FibroFind CSO co-authors Nature paper on the biology of senescence

Our senior staff members Fiona Oakley, Lee Borthwick and Lee Reed make important contributions to this exciting paper published in Nature magazine which describes how senescence induced by liver injury can spread to other organs in the body; this a process that can cause extrahepatic damage and multi-organ dysfunction. FibroFind carried out a critical experiment that validated this concept in human tissues using their precision-cut tissue slice platform. Congratulations to Fiona and the two Lee's!

At Fibrofind we're deeply committed to pioneering research and meticulously crafted drug development studies.
Every product is a culmination of months of collective dedication, passion, and precision from our team. It's imperative for us that our research samples, reach our global partners seamlessly.

Our solution lay with Biocair - our chosen logistics partner. Their unparalleled expertise ensures that every sample, precious to both us and our clients, is delivered with unmatched care. This collaboration amplifies our unwavering commitment to our clients.

Each sample holds the promise of clinical breakthroughs. With Biocair on our side, we're confidently advancing towards realising that potential for our client's products.

FibroFind where honoured to partner at this year’s 7^th Annual IPF summit annual event in Boston, USA. This event brings together world leaders in the field of idiopathic pulmonary fibrosis (IPF)

Lee Borthwick, Chief Operating Officer for FibroFind presented on day 1 on Dynamic Fibrogenesis in Human Precision – Cut Tissue Slices. He focussed on FibroFind’s unrivalled preclinical platform which is being used extensively in the development and testing of anti-fibrotic therapeutics.

It was a pleasure for FibroFind to be able to support Oasis Community Housing who help more than 1000 people a year in the Northeast and South London. They provide crisis services, supported housing, unemployment and financial skills training and help women escaping domestic abuse. Great evening hearing about some of the individuals supported by the charity.

Director and Chief Operating Officer Dr Lee Borthwick will be an Expert speaker at the upcoming 7th Annual AFDD summit.

Dr Borthwick's address entitled Dynamic Fibrogenesis in Human Precision Cut Tissue Slices: An Unrivalled Preclinical Platform for Target Identification and Testing of Novel Therapies will discuss the following:

• Human precision cut tissue slices (PCS) retain the cellular complexity and architecture
of the native tissue in culture.
• Utilizing established, dynamic models of tissue inflammation and fibrogenesis for drug
testing, target engagement and assessment of tissue viability in PCS
• Engineering PCS for pre-clinical investigations of the tumour microenvironmen

FibroFind are delighted to have supported this important conference and to be given the opportunity to present the utility of its precision cut liver slice system for the design of human models of hepatocellular carcinoma for precision oncology.

At Fibrofind we're deeply committed to pioneering research and meticulously crafted drug development studies.
Every product is a culmination of months of collective dedication, passion, and precision from our team. It's imperative for us that our research samples, reach our global partners seamlessly.

Our solution lay with Biocair - our chosen logistics partner. Their unparalleled expertise ensures that every sample, precious to both us and our clients, is delivered with unmatched care. This collaboration amplifies our unwavering commitment to our clients.

Each sample holds the promise of clinical breakthroughs. With Biocair on our side, we're confidently advancing towards realising that potential for our client's products.

Join FibroFind's representatives on Sept 13-14, 2023, at the Hynes Convention Centre in Boston, MA, for the LSX World Congress USA. This premier event stands as a beacon for partnering, strategy & investment for life science executive leaders, dedicated to connecting life science executives, strategics, and investors. Engage with top-tier Biotech, Medtech, and Healthtech CEOs, and immerse yourself in dynamic discussions and opportunities. We're eager to connect with you there!

We have recently expanded our research into the field of oncology, making a significant impact at the recent industry conference in Boston. Our Chief Scientific Officer, Professor Derek Mann, highlighted how FibroFind's innovative platforms provide a cutting-edge approach to model the tumour microenvironment (TME) using patient’s primary tumour tissue. By leveraging the complex heterogeneity of the TME, our platform opens doors for advanced oncology drug development, offering promising prospects for future breakthroughs.

The TME plays a critical role in tumour growth, metastasis and response to therapy. Understanding and effectively targeting this complex environment is key to advancing precision medicine in oncology. FibroFind's innovative approach provides researchers with a powerful tool to investigate and comprehend the TME's dynamic interactions, paving the way for novel therapeutic strategies. The company's cutting-edge platforms offer exciting opportunities to improve future oncology drug development, with the potential to revolutionise the field.

FibroFind continues to push boundaries and drive advancements in the oncology research landscape with our groundbreaking patient tumour tissue platforms. To learn more about FibroFind's innovative approach or to partner with us in this new exciting area of research, please send your details to contact@fibrofind.com

We are thrilled to share some highlights from our recent participation at the EASL Conference in Vienna! FibroFind had the privilege of showcasing our groundbreaking work at the event, and our team had an incredible time engaging with industry leaders, researchers, and professionals in the field of liver health. Our stand attracted significant attention, where we presented our patented human tissue culture platform and its potential impact on advancing liver research and therapeutics.

Here are a few snapshots capturing the energy and enthusiasm we experienced throughout the conference. Stay tuned for more updates on our journey as we continue to push the boundaries of innovation in liver health.

Nonalcoholic steatohepatitis (NASH) might soon become the leading
cause of end-stage liver disease and indication for liver transplantation
worldwide.

FibroFind take our corporate social responsibility very seriously and have invested significantly in local communities through various charities, schools, groups and clubs. Our support of Oasis Community Housing is something in which we take particular pride and to celebrate our contribution we have been presented with a Shared Value Award at the charities flagship Black & Gold Ball fundraiser on Friday (19 May).

Dr Lee Borthwick (Chief Operations Officer of Fibrofind), leads new project aimed at developing a human tissue slice based cardiac fibrosis model to replace certain rodent studies.

We are delighted to announce that FibroFind have been shortlisted for the prestigious Bionow Export Award for 2022.

The Bionow Awards Dinner & Ceremony is a highlight of our sector, celebrating individuals and companies who have made real impact across the year and showcasing the very best of our industry.

The event to be held beneath the wings of Concorde in March 2023 is set to be a fantastic evening and all of FibroFind will be holding our breath when the envelope is opened.

FibroFind are pleased to announce our attendance at the CKD Summit in Boston, Massachusetts on 7-9^th March 2023.

This 5^th Chronic Kidney Disease Drug Development Summit has been described as “powerful” by previous attendees with an excellent range of key players speaking on the hottest topics in this field from a Pharma and Biotech perspective.

Our own Dr Lee Borthwick, Chief Operating  Officer at FibroFind will be exploring the following topics as a speaker on day 2 of the conference;

• Human precision cut kidney slices (PCKS) retain the cellular complexity and architecture of the native tissue in culture
• Established, dynamic models of tissue inflammation and fibrogenesis in PCKS
• Application of PCKS for drug testing, target engagement and assessment of tissue viability

Please attend along and join the conversation by following the link 

Thank you to all who attended our 2022 AGM, held on the 15th November 2022.

Despite difficult times in many sectors 2021 / 2022 was another year of incredible growth for FibroFind, showing an excellent financial return alongside technical advancements and increasing our Global footprint and client base. Our team has also grown, bringing in new areas of expertise which will support our planned expansion both technically and from a business point of view.

The opening of our Istanbul branch has brought an opportunity to focus on R&D with a dedicated team of professionals focussing on the future of preclinical drug development.

We look forward to another hugely successful year with many exciting new developments in our journey…. Watch this space!

FibroFind are extremely proud of the technology we have developed inhouse to support our unique position in the market.

We have created two new videos for Liver and Kidney which explain our patented PCS (Precision Cut Slice) Technology which can be found on the ‘Solutions’ page of this website. Click below to view our Liver video with the Kidney model to follow shortly.

Please join us in welcoming Ben Gilhespy to the executive team.

To support our continued growth it was recognised that a business person was needed to look after the none technical aspects of FibroFind, allowing the team to concentrate on developing into new markets, technologies and geographies.

Ben has spent many years supporting sme’s in their growth whilst working on a wide range of boards across most sectors, so was an ideal fit for FibroFind. He said that “this is an incredible business who have developed into an exciting market. They have taken their years of academic expertise into the commercial arena, forging relationships with some of the worlds leading companies in the field of drug development. To say that I am proud to join the team and be a part of this amazing business is an understatement.”

Receiving external recognition for the success of a business is always a proud moment and FibroFind are extremely excited to announce that we have been awarded ‘Start up of the Year 2021’ at the recent Bionow Awards hosted in 2022.This award follows a year of significant growth despite turbulent international markets.

Bionow identified FibroFind as a preclinical drug development organisation specialising in fibrosis and chronic disease who use innovative approaches to develop biomedical services, equipment or products particularly those which serve the needs of human healthcare.

A very proud moment for a great team.

The whole team is extremely proud of being shortlisted in two categories for the Bionow Awards 2021: Bionow Start-Up of the Year and Bionow Export Award!

This nomination is the result of the daily dedication and passion of our amazing team for the delivery of outstanding services.

The whole team is so excited and will attend the award ceremony on March 31st, at the Concorde Conference Centre. Fingers Crossed!

ECM 2022, held on 23-25 June 2022 is the first international extracellular matrix pharmacology congress.

"The aim of the ECM2022 congress is to focus on development of new drugs targeting the extracellular matrix and improve our understanding of changes to the extracellular matrix across chronic diseases."

Source: https://ecm-congress.org/

Hepion Pharmaceuticals announced the results of a nonclinical research study conducted with Fibrofind showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer.

Additionally, CRV431 was as effective at decreasing tumor burden as an anti-PD1 antibody immune checkpoint inhibitor, PD1 antibody, and produced more beneficial changes in tumor-infiltrating cells compared to anti-PD1 antibody treatment.

FibroFind is proud to share the poster showing the results of a study carried out for one of our clients, a major pharmaceutical company, Gilead Sciences, Inc.

The poster was originally displayed at the recent European Association for the Study of the Liver (EASL) annual meeting (ILC2021). Using its patented bioreactor and human precision-cut tissue slices (PCLS), FibroFind have tested Gilead’s novel compound in a setting of fatty liver.

Based on the data collected from three human donors, Gilead conclude in the summary of the poster “these data are similar to improvements in steatosis and fibrosis observed in patients with NASH treated with FIR and CILO combination therapy, and suggest human PCLS as a promising translational model to evaluate future NASH therapies”

FibroFind collaborates to discover mTORC1-Plin3-regulated lipophagy protects against fatty liver disease.

We are excited to announce the publication of an important collaborative study with the Newcastle Fibrosis Research Group where we applied our precision-cut liver slice (PCLS) bioreactor technology to discover a naturally occurring mechanism that guards against the unhealthy build-up of fat in hepatocytes which affects up to 1 billion people worldwide and can lead to chronic liver disease and/or development of liver cancer.

​Neutrophils induce paracrine telomere dysfunction and senescence in a ROS-dependant manner.

Derek Mann, Chief Scientific Officer, explains that the use Fibrofind's PCLS Technology "adds an important human science angle to a story about how neutrophils which are perhaps the most important cells for tackling infections, promote tissue ageing".

This paper is published in The EMBO Journal is accessible under Open Souce Licence.

Our CEO, Jelena Mann, will present our Precision-Cut Liver Slice technology at the 4th Annual NASH Summit and its use in the preclinical phase of the Drug Development process.

Click below to learn more about the NASH summit or contact us to enquire about the PCLS technology and our related services.

On November 17th, 2020, Dr Lee Borthwick, our Chief Operation Officer presented our patented Pricesion-Cut Slice technology and its use for the modelling of Fibrosis in pre-clinical trials at 4th Annual AFDD summit.

If you missed this talk and want to know more about the PCS technology get in touch with us!

On November 9th 2020, Nature Metabolism has published an article resulting from a research project led by the Newcastle Fibrosis Research Group that uses Fibrofind's Precision-cut Liver Slices technology.

The paper entitled "c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis"

The complete article is available on open access.

A shareholders meeting will be held on Thursday, September 17th 2020, from 12:00 to 12:30 to discuss and approve the following resolution:

- Resolution 1: The transfer of the intellectual property from Fibrofind Ltd to Fibrofind IP Ltd.

All shareholders are invited to contact Jeremy Domis (jeremy.domis@fibrofind.com) to receive information about the location of the meeting.

In a new study ran for Hepion's Pharmaceuticals, Fibrofind demonstrate that Hepion's drug candidate, CRV431, first tested on Liver shows efficacy on idiopathic pulmonary fibrosis.

Jelena Mann and Lee Borthwick, respectively CEO and COO of Fibrofind will be present and present our Precision-Cut Slice technology at the 4th Annual NASH Summit

From February 19-23, three of our directors attended Keystone Symposia on Fibrosis and Tissue Repair, with our COO, Dr. Lee Borthwick, presenting our Precision-Cut Slice technology

Read our Precision-Cut Liver Slice technology paper published in Hepatology Journal

​Hepion Pharmaceutical's NASH drug shows remarkable efficacy in a Precision-cut Liver slice Study on human tissue preformed by Fibrofind

Great results on testing its CRV431 compound in a Fibrofind PCLS Study leads to impressive results on Hepion's value on the Nasdaq Stock Exchange

Last September, Vicore Pharma Holding a clinical-stage pharmaceutical company announced the positive results obtained testing their drug candidate VP01 on IPF lung tissue using Fibrofind's Precision-Cut Slices platform.

The human tissue slice culture platform of FibroFind is to be critical for a delivery of a new MRC funded grant on which the Newcastle Fibrosis Research Group are partnering with the company to discover new biology in the field of cellular senescence. The grant builds on previous work carried out in collaboration with Dr Joao Passos and colleagues at the Mayo institute, Rochester. The latest exciting publication on this collaboration is now out in Nature describing an important role of mitochondrial DNA in regulating the pro-inflammatory senescence associated secretory phenotype.